Pharmaceutical Technology, Aug 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Aug 1, 2012
Articles
CROs and CMOs Have Cause to Celebrate
By Jim Miller
Annual survey shows strong growth for service providers and promises to continue into 2013.
Quality by Design: A Contract Organization's Perspective
By Anil Kane
The author discusses how a CDMO helps in gaining process understanding and in developing robust, high-quality products and processes.
A Manufacturing Capacity-Sharing Model: Merck & Co. and MedImmune LLC
By Patricia Van Arnum
The manufacturing capacity-sharing model in biologics and Merck & Co. and MedImmune ushers in a new paradigm of "co-opetition".
Market Strengths and Weaknesses in Biosimilars
By Patricia Van Arnum
An examination of the current and projected market for biosimilars, development costs for biosimilars compared with small-molecule generic drug, and partnerships in biosimilars.
Strategies in Outsourcing: Insourcing Emerges as an Alternative Model
By Patricia Van Arnum
AMRI, a contract research and manufacturing organization, discusses its adaption of an insourcing model with Eli Lilly.
Strategies in Outsourcing Facilities Management
By Rakesh Kishan , Andrew Cieslak
The authors highlight costs, benefits, and implementation success factors across first, second, and third generations of facility management outsourcing contracts.
Size Associations in the CRO Outsourcing Relationship
By Janice Hutt
The author provides results and commentary on a survey analyzing outsourcing strategies, practices, challenges, and outcomes in the selection of a CRO.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here